ReviewJournal of clinical medicine2025
Retinal Biomarkers in Diabetic Retinopathy: From Early Detection to Personalized Treatment.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis.PloS one · 2025Pooled it
- Clinical-guided deep learning framework for diabetic retinopathy: integrating lesion-aware attention, adversarial augmentation, and uncertainty quantification.Scientific reports · 2026Article
- Article
- Retinal Ischemic Perivascular Lesions Screen for Vision-Threatening Diabetic Retinopathy Visualized on Ultra-Widefield Fluorescein Angiography.Translational vision science & technology · 2026Article
- Retinal Ischemic Perivascular Lesions are Associated with Multifactorial Disease Burden and Severity of Diabetic Retinopathy.Ophthalmology science · 2026Article
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.Cell death discovery · 2026Article
- Oxidative Stress in Diabetic Retinopathy: Pathogenic Mechanisms, Biomarkers and Clinical Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Inflammatory Biomarkers in Diabetic Macular Edema.Journal of clinical medicine · 2026Review
- Diabetic retinopathy: why some eyes suffer more - a focus on retina-specific risk factors and metabolic memory.Journal of translational medicine · 2026Review
- Monitoring Systemic Inflammatory Indices and Retinal Changes Over Time Following Initial Diagnosis of Diabetic Retinopathy.Journal of ophthalmology · 2026Article
- Precision Medicine in Diabetic Retinopathy: The Role of Genetic and Epigenetic Biomarkers.Journal of clinical medicine · 2025Review
- Exploring the Relationship Between Health Biomarkers and Performance on a Novel Color Perimetry Device in Prediabetes and Type 2 Diabetes.Diabetology · 2025Article
- The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues.Cells · 2025Review
- Aqueous humor levels of syndecan-1 and syndecan-4 associated with OCTA metrics in diabetic retinopathy.Frontiers in medicine · 2025Article
- Analysis of OCT-Based Biomarkers and Recurrence in Eyes with Diabetic Macular Edema Following Anti-VEGF Therapy.International journal of general medicine · 2025Article
- Identifying neonatal hyperglycemia thresholds in preterm infants based on retinopathy of prematurity outcomes: proof-of-concept study.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a leading cause of vision loss globally, with early detection and intervention critical to preventing severe outcomes. This narrative review examines the role of retinal biomarkers-molecular and imaging-in improving early diagnosis, tracking disease progression, and advancing personalized treatment for DR. Key biomarkers, such as inflammatory and metabolic markers, imaging findings from optical coherence tomography and fluorescence angiography and genetic markers, provide insights into disease mechanisms, help predict progression, and monitor responses to treatments, like anti-VEGF and corticosteroids. While challenges in standardization and clinical integration remain, these biomarkers hold promise for a precision medicine approach that could transform DR management through early, individualized care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.